Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2009;40:S34-S37
Published online before print December 8, 2008, doi: 10.1161/STROKEAHA.108.534917
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/3_suppl_1/S34    most recent
STROKEAHA.108.534917v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsh, B. J.
Right arrow Articles by Stenzel-Poore, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, B. J.
Right arrow Articles by Stenzel-Poore, M. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Encephalitis
Related Collections
Right arrow Other Stroke Treatment - Medical

(Stroke. 2009;40:S34.)
© 2009 American Heart Association, Inc.


Imaging and Biomarkers

Inflammation and the Emerging Role of the Toll-Like Receptor System in Acute Brain Ischemia

Brenda J. Marsh, BS; Susan L. Stevens, BS; Brian Hunter, BS Mary P. Stenzel-Poore, PhD

From the Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Ore.

Correspondence to Mary P. Stenzel-Poore, PhD, Department of Molecular Microbiology and Immunology, L220, Oregon Health & Science University, 3181 Sam Jackson Park Road, Portland, OR 97239. E-mail poorem{at}OHSU.edu

Background and Purpose— Systemic administration of cytosine-guanine (CpG) oligodeoxynucleotides provides neuroprotection against subsequent cerebral ischemic injury. We examined the genomic response of leukocytes and brain cells after ischemia in the context of CpG preconditioning.

Methods— RNA was isolated from circulating leukocytes and ischemic cortex 3 and 24 hours after middle cerebral artery occlusion after CpG or saline pretreatment and subjected to microarray analysis. Genes uniquely upregulated in CpG-pretreated mice were examined for overrepresented transcriptional regulatory elements.

Results— CpG preconditioning induced a novel response to middle cerebral artery occlusion within circulating leukocytes that was dominated by natural killer cell-associated genes and the GATA-3 transcriptional regulatory element. Preconditioning also caused a novel brain response to stroke that was dominated by Type I interferon, interferon-associated genes, and transcriptional regulatory elements.

Conclusion— CpG preconditioning invokes novel leukocyte and brain responses to stroke. In this, CpG may be a unique preconditioning agent, coordinating peripheral and brain responses to protect against ischemic injury.


Key Words: inflammation • hypoxia-ischemia • stroke